Topas, Boehringer partner for immune tolerance candidates for cancer

Topas Therapeutics GmbH (Hamburg, Germany) partnered with Boehringer Ingelheim GmbH (Ingelheim, Germany) to develop antigen-specific tolerance-generating adjuvant candidates delivered via virus-based vectors. The collaboration will initially focus on cancer.

Topas will be responsible for the production of the tolerizing molecules and Boehringer will contribute its antigen and pharmacology knowledge. Boehringer has an option to license several preclinical candidates developed under the collaboration. Financial terms are undisclosed...